About the Cover: Immunohistochemical staining shows strong poly-ADP-ribosylation in tumor tissue of breast cancer patient while adjacent tissue shows negative programmed death-ligand-1 expression (not shown here). See article by Jiao and colleagues.

Read: FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma, Julia A. Beaver, et al.